A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants.

Autor: Malik FI; Research and Development, Cytokinetics, Inc, South San Francisco, California, USA., Robertson LA; Research and Development, Cytokinetics, Inc, South San Francisco, California, USA., Armas DR; Celerion, Inc, Tempe, Arizona, USA., Robbie EP; Research and Development, Cytokinetics, Inc, South San Francisco, California, USA., Osmukhina A; Research and Development, Cytokinetics, Inc, South San Francisco, California, USA., Xu D; Research and Development, Cytokinetics, Inc, South San Francisco, California, USA., Li H; Certara, Inc, Menlo Park, California, USA., Solomon SD; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Publikováno v: JACC. Basic to translational science [JACC Basic Transl Sci] 2022 Aug 10; Vol. 7 (8), pp. 763-775. Date of Electronic Publication: 2022 Aug 10 (Print Publication: 2022).